Zheng Yizhong, Tai Jian Eu, Yee Brendon J
Sleep and Circadian Research Group, Woolcock Institute of Medical Research, Sydney, Australia.
Department of Respiratory and Sleep Medicine, St George Hospital, Sydney, Australia.
Breathe (Sheff). 2024 Nov 12;20(3):230235. doi: 10.1183/20734735.0235-2023. eCollection 2024 Oct.
Central sleep apnoea (CSA) is characterised by recurrent episodes of airway cessation or reduction in the absence of respiratory effort. Although CSA is less common than obstructive sleep apnoea, it shares similar symptoms. CSA can be secondary to various medical conditions, high altitude and medication exposure. CSA can also emerge during obstructive sleep apnoea therapy. There are a range of treatment options and selecting the right therapy requires an understanding of the pathophysiology of CSA. This review explores the aetiology, pathophysiology and clinical management of non-hypercapnic CSA.
中枢性睡眠呼吸暂停（CSA）的特征是在无呼吸努力的情况下反复出现气道停止或减少。尽管CSA不如阻塞性睡眠呼吸暂停常见，但它具有相似的症状。CSA可能继发于各种医疗状况、高海拔和药物暴露。CSA也可能在阻塞性睡眠呼吸暂停治疗期间出现。有一系列治疗选择，选择正确的治疗方法需要了解CSA的病理生理学。本综述探讨了非高碳酸血症性CSA的病因、病理生理学和临床管理。
